Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide Impact on EPCs and MSCs in T2DM
NCT04126603Phase 4Completed
- Start
- Aug 2019
- Primary completion
- Oct 2023
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Placebo with Semaglutide (2 arms). Primary endpoints: CD34+ Endothelial Progenitor Cell Number Per Mononuclear Cells Ratio at 24 weeks, CD34+ Endothelial Progenitor Cell Migration Against Serum SDF1a Gradient at 24 weeks and 2 more. Started Aug 2019; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04126603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04126603.